

AQUARRAY WITH INNOVATIONS IN PERSONALISED MEDICINE



DMA TECHNOLOGY OPENS THE DOOR TO NEW PATHS IN PERSONALISED MEDICINE

Aquarray's DMA technology opens the door to new paths in personalised medicine. Due to the extreme miniaturisation of the test volumes, a few cells from biopsy material are sufficient to test the efficacy of various drugs in parallel on the patient's own cells. This is not possible with current methods due to the significantly higher material consumption.

This makes possible a patient-specific therapy of cancer by selecting the most effective drug therapy. This enables individualised therapy and increases the chances of successful treatment response and helps to avoid side effects due to the use of ineffective drugs.

Currently, there are over 200 approved cancer drugs in Germany alone. These often include several drugs approved for the same indication. In medical practice, the problem arises that it is not possible to predict which of the possible drugs has the best chance of success in a particular patient.

Investors and cooperation partners are being sought for the further development of this technology.

ABOUT AQUARRAY

Aquarray is a spin-off of the Karlsruhe Institute of Technology (KIT), founded based on the scientific work of Prof. Dr. Pavel Levkin. The start-up was established with the support of the ERC Proof-of-Concept Grant of the European Union and the Horizon 2020 research and innovation programme of the European Union under grant agreement No. 880019.

Contact for more information:

Dr. Tim Friedrichson, CEO (tim.friedrichson@aquarray.com)

Harry Böltz, Head of Sales (harry.boeltz@aquarray.com)

Prof. Dr. Festel Gunter Festel, Cooperations (gunter.festel@aquarray.com)